Synonym: Purinergic Receptor P2Y12, SP1999, P2Y12, HORK3, Purinergic Receptor P2Y G-Protein Coupled 12, P2Y12 Platelet ADP Receptor, ADP-Glucose Receptor, P2Y Purinoceptor 12, P2Y(ADP), P2Y(Cyc), P2T(AC), P2Y(AC), ADPG-R, Putative G-Protein Coupled Receptor, G-Protein Coupled Receptor SP1999, Gi-Coupled ADP Receptor HORK3, Purinergic Receptor P2RY12, P2Y(12)R, BDPLT8

About Human Purinergic Receptor P2Y12 (P2RY12) Stable Cell Line

Purinergic Receptor P2Y12 (P2RY12), commonly known as the P2Y12 receptor, is a Class A G protein-coupled receptor (GPCR) that serves as a key receptor for adenosine diphosphate (ADP). P2RY12 is predominantly expressed on platelets, where it plays a central role in platelet activation, aggregation, and thrombus formation. The receptor is also expressed in microglia within the central nervous system and has emerging roles in neuroinflammation and immune regulation. Upon activation by ADP, P2RY12 primarily couples to Gi proteins, resulting in inhibition of adenylate cyclase activity, reduction of intracellular cAMP levels, activation of PI3K signaling pathways, and amplification of platelet activation responses.

P2RY12 is an essential mediator of hemostasis and thrombosis. During vascular injury, ADP released from activated platelets binds to P2RY12, triggering signaling pathways that stabilize platelet aggregates and promote clot formation. Because of its pivotal role in platelet function, P2RY12 has become one of the most important therapeutic targets in cardiovascular medicine. Several widely prescribed antiplatelet drugs, including clopidogrel, prasugrel, ticagrelor, and cangrelor, exert their effects through inhibition of P2RY12 signaling. In addition to cardiovascular disease, P2RY12 has attracted increasing interest in neuroscience due to its involvement in microglial activation, neuroimmune communication, and neurodegenerative disorders.

eEnzyme's Human P2RY12 Stable Cell Line provides a reliable and reproducible cellular platform for investigating P2RY12-mediated signaling pathways and evaluating receptor-targeted therapeutics. The cell line enables quantitative assessment of ADP analogs, agonists, antagonists, inhibitory antibodies, and novel receptor modulators through cAMP assays, reporter gene assays, β-arrestin assays, and other GPCR functional screening platforms. Researchers can utilize this stable cell line for receptor characterization, compound profiling, potency determination, lead optimization, and high-throughput screening applications supporting cardiovascular, hematology, and neuroscience drug discovery programs.

Applications of the P2RY12 Stable Cell Line

• P2RY12 receptor pharmacology studies
• ADP-mediated signaling investigations
• Antiplatelet drug discovery and development
• Agonist and antagonist screening
• Platelet activation and thrombosis research
• Cardiovascular disease studies
• cAMP and GPCR functional assays
• High-throughput screening applications

Biological Significance of P2RY12

P2RY12 is a critical regulator of platelet activation and thrombus stabilization. Activation of the receptor by ADP amplifies platelet aggregation responses and promotes formation of stable hemostatic plugs following vascular injury. Because of its central role in thrombosis, P2RY12 inhibition has become a cornerstone of treatment for acute coronary syndrome, myocardial infarction, ischemic stroke, and patients undergoing percutaneous coronary intervention (PCI). Beyond platelet biology, P2RY12 is highly expressed by microglia in the central nervous system, where it regulates immune surveillance, neuronal communication, and responses to tissue injury. Emerging evidence suggests that altered P2RY12 signaling may contribute to neuroinflammation, neurodegenerative diseases, and central nervous system disorders. Because of its importance in both cardiovascular and neurological biology, P2RY12 remains a highly valuable target for translational research and drug development. The P2RY12 Stable Cell Line provides a powerful tool for studying purinergic receptor biology and advancing the discovery of next-generation therapeutics targeting thrombosis, inflammation, and neuroimmune disorders.